[{"address1": "1210-1220 Washington St.", "address2": "Suite 210", "city": "Newton", "state": "MA", "zip": "02465", "country": "United States", "phone": "617 344 4190", "website": "https://acumenpharm.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.", "fullTimeEmployees": 61, "companyOfficers": [{"maxAge": 1, "name": "Mr. Daniel J. O'Connell M.B.A.", "age": 55, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 1047590, "exercisedValue": 0, "unexercisedValue": 1034567}, {"maxAge": 1, "name": "Dr. James  Doherty Ph.D.", "age": 57, "title": "President & Chief Development Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 730785, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Zuga", "title": "CFO & Chief Business Officer", "fiscalYear": 2024, "totalPay": 703157, "exercisedValue": 0, "unexercisedValue": 254161}, {"maxAge": 1, "name": "Dr. Grant A. Krafft Ph.D.", "title": "Co-Founder", "fiscalYear": 2024, "totalPay": 42000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Caleb E. Finch Ph.D.", "title": "Co-Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William L. Klein Ph.D.", "title": "Co-Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Russell  Barton M.S.", "age": 67, "title": "Chief Operating Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 223680, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kelly  Carranza", "title": "Vice President, Finance & Accounting and Corporate Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alex  Braun M.B.A.", "title": "VP & Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Derek M. Meisner Esq., J.D.", "age": 54, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 752945, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1767225600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.86, "open": 1.85, "dayLow": 1.71, "dayHigh": 1.85, "regularMarketPreviousClose": 1.86, "regularMarketOpen": 1.85, "regularMarketDayLow": 1.71, "regularMarketDayHigh": 1.85, "payoutRatio": 0.0, "beta": 0.236, "forwardPE": -1.0429991, "volume": 280477, "regularMarketVolume": 280477, "averageVolume": 221780, "averageVolume10days": 206890, "averageDailyVolume10Day": 206890, "bid": 1.52, "ask": 2.63, "bidSize": 2, "askSize": 2, "marketCap": 109637896, "fiftyTwoWeekLow": 0.855, "fiftyTwoWeekHigh": 2.46, "allTimeHigh": 26.98, "allTimeLow": 0.855, "fiftyDayAverage": 1.9615, "twoHundredDayAverage": 1.489245, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 13864899, "profitMargins": 0.0, "floatShares": 35610511, "sharesOutstanding": 60573425, "sharesShort": 568193, "sharesShortPriorMonth": 1318100, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.0094, "heldPercentInsiders": 0.06837, "heldPercentInstitutions": 0.64735, "shortRatio": 3.71, "shortPercentOfFloat": 0.0126, "impliedSharesOutstanding": 60573425, "bookValue": 1.538, "priceToBook": 1.1768531, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -133351000, "trailingEps": -2.21, "forwardEps": -1.73538, "enterpriseToEbitda": -0.1, "52WeekChange": 0.16981137, "SandP52WeekChange": 0.18594909, "quoteType": "EQUITY", "currentPrice": 1.81, "targetHighPrice": 10.0, "targetLowPrice": 4.0, "targetMeanPrice": 6.4, "targetMedianPrice": 6.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 126609000, "totalCashPerShare": 2.09, "ebitda": -138170000, "totalDebt": 30836000, "quickRatio": 5.799, "currentRatio": 6.019, "debtToEquity": 33.095, "returnOnAssets": -0.42226002, "returnOnEquity": -0.85929, "grossProfits": -118928000, "freeCashflow": -78959504, "operatingCashflow": -123657000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ABOS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1625146200000, "corporateActions": [], "postMarketTime": 1767995245, "regularMarketTime": 1767992401, "exchange": "NMS", "messageBoardId": "finmb_8539521", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -2.68818, "regularMarketPrice": 1.81, "shortName": "Acumen Pharmaceuticals, Inc.", "longName": "Acumen Pharmaceuticals, Inc.", "marketState": "CLOSED", "postMarketChangePercent": -2.7624283, "postMarketPrice": 1.76, "postMarketChange": -0.049999952, "regularMarketChange": -0.0500001, "regularMarketDayRange": "1.71 - 1.85", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 221780, "fiftyTwoWeekLowChange": 0.9549999, "fiftyTwoWeekLowChangePercent": 1.116959, "fiftyTwoWeekRange": "0.855 - 2.46", "fiftyTwoWeekHighChange": -0.6500001, "fiftyTwoWeekHighChangePercent": -0.2642277, "fiftyTwoWeekChangePercent": 16.981136, "earningsTimestampStart": 1762867800, "earningsTimestampEnd": 1762867800, "earningsCallTimestampStart": 1755000000, "earningsCallTimestampEnd": 1755000000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.21, "epsForward": -1.73538, "epsCurrentYear": -2.28474, "priceEpsCurrentYear": -0.79221267, "fiftyDayAverageChange": -0.1515001, "fiftyDayAverageChangePercent": -0.07723686, "twoHundredDayAverageChange": 0.3207549, "twoHundredDayAverageChangePercent": 0.21538086, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-07-01", "cryptoTradeable": false, "displayName": "Acumen Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2026-01-10"}]